Global Dermatophytic Onychomycosis Therapeutics (DOT) Market was valued at US$ 5.47 Bn in 2021, and is expected to grow 1.9X by 2031

Advancements in medicine, diagnosis of varieties of illnesses, and increasing elder population at an unprecedented rate have resulted in high demand for novel drugs and therapies for dermatophytic onychomycosis treatment. In 2021, the dermatophytic onychomycosis therapeutics market was valued at nearly US$ 5.5 Bn, and is set to experience a 6.5% CAGR over the forecast period (2022-2031).

Request For Free Sample Report of "Dermatophytic Onychomycosis Therapeutics Market"@ https://www.persistencemarketresearch.com/samples/5840

Presence and availability of a large clinical pipeline with reference to therapeutic approaches based on dermatophytic onychomycosis treatment are set to drive market growth over the coming years. According to the European Commission, more than one fifth, i.e., 20.3% of the population in EU-27 countries was aged 65 and over in 2020. According to WHO, approximately, 80% to 85% of onychomycosis occurs in patients aged above 50 years. High prevalence of age-related disease incidence has led to an increase in the demand for biologics for therapeutic induction for dermatophytic onychomycosis treatment.

Furthermore, social conditions such as poverty, race, and social groups possess an extremely varied rate of occurrence of onychomycosis. These social disparities, together with the presence of a large populace under poverty, is a chief driver of the growth of onychomycosis.

Companies

Bausch Health
Galderma S.A.
Novartis AG
Pfizer, Inc.
Moberg Pharma AB
Bayer AG
Dr. Reddy's Laboratories Ltd.

Buy Full Report Now and Get Up to 20% Discount @ https://www.persistencemarketresearch.com/checkout/5840

Key Takeaways from Market Study

By treatment type, drugs are expected to hold 74.8% market value share by the end of 2032, primarily due to rising activities by key players in the drug development biosphere.
Distal subungual onychomycosis, by indication, is leading with 78.3% market share in 2021, owing to it being a common factor of occurrence associated with age.
The male segment, by gender, is leading with 61.7% market share in 2021, Males are reported to be more susceptible to onychomycosis with the most probable associated hypothesis being occupational factors as well as lower treatment compliance.
Age group between 18-39 years is expected to hold more than half of the market value share by the end of 2032.
Retail sales dominated the end user segments with a share of around 56.2% in 2021.
By region, North America is the leading region with an expected value share of 48.4% by 2032.

"Rising geriatric population and high prevalence of onychomycosis in the elderly age group are set drive dermatophytic onychomycosis therapeutics," says an analyst of Persistence Market Research.

Market Competition

Key market players such as Bausch Health and Dr. Reddy's Laboratories, amongst others, are involved in research activities in the life sciences sphere. These key players also imbibe the strategy of partnerships and strategic collaborations to expand their geographical product footprint and drive sales is emerging economical territories.

For instance, in December 2021, Bausch Health Ortho Dermatologics the announced JUBLIA® (efinaconazole) Topical Solution, 10%, for onychomycosis treatment, which has received the American Podiatric Medical Association (APMA) seal of approval.
In June 2020, Dr. Reddy's Laboratories acquired the branded generics business of Wockhardt Limited in Indiam Nepal, Sri Lanka, Bhutan, and the Maldives.

Request Customization @ https://www.persistencemarketresearch.com/request-customization/5840

 Key Questions Answered in This Report.

What are the Roadblocks for Dermatophytic Onychomycosis Therapeutics Suppliers?
What are the Key Opportunities for Dermatophytic Onychomycosis Therapeutics Manufacturers?
How is Focus on Safety Influencing Dermatophytic Onychomycosis Therapeutics Demand?
What is the Regulatory Impact on Global Sales of Dermatophytic Onychomycosis Therapeutics?
Which Region Offers the Largest Opportunity for Sales of Dermatophytic Onychomycosis Therapeutics?
Where Does the U.S. Stand in the Market for Dermatophytic Onychomycosis Therapeutics?
What Is the Outlook for Dermatophytic Onychomycosis Therapeutics Manufacturers in China?
Why is Germany a Lucrative Market for Dermatophytic Onychomycosis Therapeutics Manufacturers?
Why Will Belgium Outpace Other European Markets for Dermatophytic Onychomycosis Therapeutics?
Why is There High Demand for Tires in Dermatophytic Onychomycosis Therapeutics?
Why are Sales of Dermatophytic Onychomycosis Therapeutics Surging?

Related Market Reports:

Neuropathic Pain Market: https://www.persistencemarketresearch.com/market-research/neuropathic-pain-market.asp

Human Insulin Market: https://www.persistencemarketresearch.com/market-research/human-insulin-market.asp

Media Contact:
Persistence Market Research
305 Broadway,7th Floor New York City, NY 10007 United States
Call +1-646-568-7751
Call +1 800-961-0353
sales@persistencemarketresearch.com

About Us

Persistence Market Research is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients' business needs.

This release was published on openPR.